Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk
Omada for Cholesterol closes a critical gap in cardiovascular care, delivering between-visit support for the many adults whose LDL remains uncontrolled under usual care¹
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, today announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol,
“High cholesterol rarely exists in isolation
High cholesterol is a core driver of cardiovascular risk
“Launching with a market-leading employer is a signal that there is a need for between-visit cholesterol care that properly addresses long-term cardiovascular risk in their populations,” said Sean Duffy, CEO & Co‑Founder of Omada Health. “Because of our flexible infrastructure, we were able to quickly add cholesterol support on our existing platform, giving customers one partner for integrated cardiometabolic care in response to their demand.”
Omada for Cholesterol is designed to complement primary and specialty care by addressing how cardiovascular risk builds over time, not just how it’s measured in visits. By keeping members engaged in day-to-day behavior change across nutrition, activity, and medication adherence, Omada helps bend the curve of cardiovascular disease, rather than reacting only after acute events occur.
About Omada Health
Omada Health (Nasdaq: OMDA) is on a mission to fix what’s broken in chronic care. Today's healthcare system poorly serves chronic conditions that require ongoing support between doctor visits, like obesity, diabetes, hypertension, and musculoskeletal disorders. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than one million members since launch across 2,000+ employers, health plans, and health systems. Learn more at omadahealth.com.
Contacts
Rose Ramseth
Citations
- Lim Y, Haq N, Boster J. Obesity and comorbid conditions. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024. Available at: .
- MacDougall DE, Ferdinand K, Baum SJ, et al. Cholesterol management in US adults with ASCVD in the Family Heart Database during 2022–23: Current state of care and opportunities for improvement. Am J Prev Cardiol. 2025;24:101354. doi:10.1016/j.ajpc.2025.101354.
- American Heart Association. Know your risk factors for high blood pressure. Available at: . Accessed February 12, 2026.
- Centers for Disease Control and Prevention. Prevalence of self-reported high cholesterol in adults with diabetes, aged 18 years or older, United States, 2021. Behavioral Risk Factor Surveillance System. Available at: . Accessed February 12, 2026.
- American Heart Association. Prevention and treatment of high cholesterol (hyperlipidemia). Available at: . Accessed February 12, 2026.
- American Heart Association. Lifestyle changes to prevent a heart attack. Available at: . Accessed February 12, 2026.
- Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;[Epub ahead of print].
- Castro Sweet CM, Chiguluri V, Gumpina R, et al. Outcomes of a Digital Health Program With Human Coaching for Diabetes Risk Reduction in a Medicare Population. J Aging Health. 2018;30(5):692-710. doi:10.1177/0898264316688791
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound extends losing streak against US Dollar, US PPI in focus

Barclays: US-Iran conflict unlikely to end in next 12 months, oil exports near 85% of pre-war level

Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.

Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
